Rankings
▼
Calendar
REGN Q4 2016 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
REGN
Regeneron Pharmaceuticals, Inc.
$81B
Q4 2016 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.2B
Gross Profit
$1.1B
91.6% margin
Operating Income
$347M
28.3% margin
Net Income
$253M
20.6% margin
EPS (Diluted)
$2.19
QoQ Revenue Growth
+0.5%
Cash Flow
Operating Cash Flow
$378M
Free Cash Flow
$227M
Stock-Based Comp.
$155M
Balance Sheet
Total Assets
$7.0B
Total Liabilities
$2.5B
Stockholders' Equity
$4.4B
Cash & Equivalents
$535M
Revenue Segments
Antibody Collaboration
$71M
54%
Immuno-oncology Agreement
$61M
46%
← FY 2016
All Quarters
Q1 2017 →
